7 GLP-1 Side Effects to Expect, Week by Week
HealthCentral mapped the GLP-1 side effect timeline. Here's what FDA labels and peer-reviewed research actually back up.
Now I have everything I need. Let me write the article.
HealthCentral dropped a piece this week laying out what GLP-1 side effects actually look like — not in a clinical trial footnote, but week by week, in real time. It's worth unpacking, because the gap between "I knew nausea was possible" and "I didn't know it would hit like this on week three" is where a lot of people quietly quit.
Here's what the FDA labels and the research actually say about the timeline.
The First Shot: Weeks 1–2
Your body has never felt a GLP-1 receptor agonist before. The drug slows gastric emptying — meaning food sits in your stomach longer — and signals your brain to cut appetite. That's the mechanism. The side effect is that your gut does not love this at first.
The FDA's Wegovy label lists nausea, diarrhea, vomiting, constipation, and abdominal pain as the most common adverse reactions reported at an incidence of 5% or greater. The Zepbound (tirzepatide) label lists an almost identical set — nausea, diarrhea, vomiting, constipation, abdominal pain, and dyspepsia.
Most people feel nausea most. Eating smaller meals, staying upright after eating, and avoiding greasy or spicy food in the first couple of weeks tends to help. This is the phase where you learn your new normal.
The Escalation Window: Weeks 4–8
Most GLP-1 protocols step up your dose every four weeks. Each time the dose goes up, you may feel like you're back at week one — briefly.
A 2022 study in Diabetes, Obesity and Metabolism looked specifically at gastrointestinal tolerability of once-weekly semaglutide 2.4 mg across the STEP trials. The authors found that GI adverse events were most common during the dose-escalation phase and generally resolved or decreased over time. Importantly, the study also found a relationship between GI events and weight loss — meaning the discomfort and the mechanism driving results are linked.
That's not a reason to push through severe symptoms. But it reframes mild nausea: your body is responding to the drug.
The Ones People Don't Expect: Fatigue and Hair Loss
Two side effects that catch people off guard — because they're not "stomach" problems.
Fatigue shows up on both the Wegovy and Zepbound FDA labels as a reported adverse reaction. It tends to cluster in the early weeks and at each dose step-up. Eating enough — especially protein — and staying hydrated matters more than usual during this stretch.
Hair shedding (medically called telogen effluvium) is listed on both labels as well. It typically shows up around weeks 12–20, not week one, which is why people are blindsided. It's tied to rapid caloric reduction and weight loss itself, not necessarily the drug molecule — but the timing still lines up with GLP-1 use. A 2026 community pharmacy follow-up study in Farm Comunitarios specifically flagged hair loss as one of the side effects warranting structured monitoring in patients on injectable semaglutide for weight loss.
The Serious Ones: Know the Warning Signs
The FDA labels for both Wegovy and Zepbound carry warnings for several less common but serious events that are worth knowing by name.
According to the Wegovy FDA label, these include:
- Acute pancreatitis — persistent, severe abdominal pain that may radiate to the back is a reason to stop the drug and contact your prescriber immediately.
- Acute gallbladder disease — gallstones and cholecystitis have been observed in clinical trials.
- Acute kidney injury — a downstream risk from dehydration caused by vomiting or diarrhea. Staying hydrated isn't optional.
- Heart rate increase — the label flags this and recommends monitoring at regular intervals.
The Zepbound label also lists hypersensitivity reactions including anaphylaxis and angioedema as postmarketing reports — rare, but real.
None of these are reasons to avoid GLP-1s. They're reasons to know your body while you're on one.
The Long Game: Months 3 and Beyond
Once you're at your maintenance dose and your body has adjusted, most people report that the worst GI symptoms have faded significantly. The Diabetes, Obesity and Metabolism study supports this — GI events were most concentrated in the escalation window, not the steady-state period.
What tends to linger for some people: GERD (acid reflux), constipation, and the occasional nausea flare if they eat too fast or too much. These are manageable, but they don't always fully disappear. The drug is still slowing your gastric emptying at steady state — that doesn't turn off.
What This Means for You
- Nausea and GI symptoms peak during dose escalation — each step-up may feel like a reset. This is expected and typically temporary, per the STEP trial tolerability data.
- Hair loss is real but delayed — if it shows up around month 3–5, it's likely telogen effluvium from rapid weight loss. Talk to your prescriber; it usually resolves.
- Severe abdominal pain, signs of dehydration, or allergic reactions are not "just side effects" — they're listed as warnings on the FDA labels for a reason. Go to urgent care or call your prescriber same-day.
Not medical advice. Talk to your prescriber about your specific situation, symptoms, and dosing schedule.
